To perform these analyses, we amassed a collection of 11 EGFR mutant cancer samples (from nine patients) that underwent transformation to SCLC at the time of acquired resistance to EGFR TKI therapy under the auspices of an institutional review board (IRB)-approved protocol (Supplementary Table 1). This evidence concerns the gene EGFR and cancer.